Nanjing Well Pharmaceutical Group Co.,Ltd. (SHA:603351)

SHA:603351 Revenue

Nanjing Well Pharmaceutical Group had revenue of 383.29M CNY in the quarter ending June 30, 2026, with 18.30% growth. This brings the company's total for the last twelve months to 1.40B, up 9.25% year-over-year. In the year 2025, Nanjing Well Pharmaceutical Group had annual revenue of 1.34B with 2.95% growth. That makes Nanjing Well Pharmaceutical Group the 17,115th largest company in the world by revenue and 3,098th in China.

• Revenue (ttm): 1.40B
• Revenue Growth: +9.25%
• P/S Ratio: 2.58
• Revenue / Employee: 1.95M
• Employees: 718
• Market Cap: 3.61B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Synthetic Lubricating Base Oil 900.38M 67.4%
• Medical Supplements 349.64M 26.2%
• Emulsifier 67.85M 5.1%
• Others 17.16M 1.3%

By Geography

Chart

• Eastern China 897.54M 67.7%
• Overseas 103.33M 7.8%
• North China 97.63M 7.4%
• Central China 79.68M 6.0%
• South China 54.25M 4.1%
• Southwest Region 53.60M 4.0%
• Northeast China 23.84M 1.8%
• North-West Region 15.36M 1.2%

Fiscal year ended Dec 31, 2025 See the full SHA:603351 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.34B	38.28M	2.95%
Dec 31, 2024	1.30B	140.91M	12.19%
Dec 31, 2023	1.16B	44.83M	4.03%
Dec 31, 2022	1.11B	68.70M	6.59%
Dec 31, 2021	1.04B	306.24M	41.61%

Data Source: S&P Global Market Intelligence Last updated: Aug 21, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error